Patents by Inventor Woo Young HUR

Woo Young HUR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10494346
    Abstract: The present invention relates to a novel pyrimidine-4-carboxylic acid derivative having an anticancer activity, and the compound thereof is useful as a drug for treating and preventing tumor diseases, wherein the compound is represented by the Formula 1: or a pharmaceutically acceptable salt thereof, wherein: Q is a C6-C15 aryl group; or a C4-C13 heteroaryl group, wherein the heteroaryl contains 1, 2 or 3 heteroatoms substituted with 1-3 heteroatom(s) selected from the group consisting of nitrogen, oxygen or sulfur; R is a halogen; a C1-C10 haloalkyl substituted with 1-13 halogen atom(s); a C1-C10 alkoxy; a 5- or 6-membered heterocycloalkyl or (CH2)r-R1 wherein the heterocycloalkyl contains 1-2 heteroatom(s) selected from the group consisting of nitrogen and oxygen; R1 is a hydrogen; a C1-C10 alkoxy; amino; mono(C1-C10 alkyl)amino; di(C1-C10 alkyl)amino; or —NHC(O)-phenyl; n is 1, 2, 3, 4, 5, or 6; and r is 0, 1, 2, 3, 4, 5, or 6; and m is 0, 1, 2 or 3.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: December 3, 2019
    Assignees: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Tae Bo Sim, Woo Young Hur, Ho Jong Yoon, Chi Man Song, In Jae Shun, Byeong Yun Lim, Han Na Cho, Seung Hye Choi, Gu Kong, Jeong Yeon Lee
  • Patent number: 10442796
    Abstract: The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: October 15, 2019
    Assignees: Korea Institute of Science and Technology, Daegu-Gyeongbuk Medical Innovation Foundation
    Inventors: Tae Bo Sim, Woo Young Hur, Chi Man Song, Ho Jong Yoon, Seung Hye Choi, Han Na Cho, Hwan Geun Choi, Nam Doo Kim, Jung Beom Son, Eun Hwa Ko, Hyun Kyoung Kim, Joong Heui Cho, Seock Yong Kang, So Young Kim, Yi Kyung Ko, Seung Yeon Lee, Suk Kyoon Yoon, Jae Hyun Bae
  • Publication number: 20190135765
    Abstract: The present invention relates to a novel pyrimidine-4-carboxylic acid derivative having an anticancer activity, and the compound of the present invention is useful as a drug for treating and preventing tumor diseases.
    Type: Application
    Filed: March 30, 2017
    Publication date: May 9, 2019
    Inventors: Tae Bo SIM, Woo Young HUR, Ho Jong YOON, Chi Man SONG, In Jae SHUN, Byeong Yun LIM, HanNa CHO, Seung Hye CHOI, Gu KONG, Jeong Yeon LEE
  • Publication number: 20190047993
    Abstract: The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.
    Type: Application
    Filed: August 16, 2018
    Publication date: February 14, 2019
    Inventors: Tae Bo Sim, Woo Young Hur, Chi Man Song, Ho Jong Yoon, Seung Hye Choi, Han Na Cho, Hwan Geun Choi, Nam Doo Kim, Jung Beom Son, Eun Hwa Ko, Hyun Kyoung Kim, Joong Heui Cho, Seock Yong Kang, So Young Kim, Yi Kyung Ko, Seung Yeon Lee, Suk Kyoon Yoon, Jae Hyun Bae
  • Publication number: 20180370922
    Abstract: The present invention relates to a 6-phenoxypyrimidine derivative, a method for preparing the compound and a pharmaceutical composition containing the compound as an active ingredient. Because the 6-phenoxypyrimidine compound represented by Chemical Formula 1 according to the present invention has an activity of inhibiting the production of nitric oxide (NO) as an inflammation-related factor, it is useful in treating and preventing inflammatory diseases including immunological diseases.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 27, 2018
    Applicant: Korea Institute of Science and Technology
    Inventors: Eun Joo ROH, Karam Mohamed Hasan Fara AHMED, So Ra PAIK, Woo Young HUR, Elkamhawy AHMED
  • Patent number: 10155767
    Abstract: The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 18, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Han Na Cho, Eun Hye Ju, Woo Young Hur, Ho Jong Yoon, Chi Man Song
  • Patent number: 10130631
    Abstract: The present invention relates to a therapeutic agent for chronic myelogenous leukemia with reduced drug-resistance and side-effects containing a 1,6-disubstituted indole compound.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 20, 2018
    Assignee: Korea Institute of Science and Technology
    Inventors: Tae Bo Sim, Ho Jong Yoon, Woo Young Hur, Yun Ju Nam, Hwan Geun Choi
  • Patent number: 10059717
    Abstract: The present invention provides a pharmaceutical composition, as an effective ingredient, a urea compound having a protein kinase inhibitory activity and containing a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one skeleton, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: August 28, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Woo Young Hur, Ho Jong Yoon, Chi Man Song, Eun Hye Ju, Han na Cho, Hwan Geun Choi
  • Publication number: 20180065970
    Abstract: The present invention provides a pharmaceutical composition, as an effective ingredient, a urea compound having a protein kinase inhibitory activity and containing a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one skeleton, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2017
    Publication date: March 8, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Woo Young HUR, Ho Jong YOON, Chi Man SONG, Eun Hye JU, Han na CHO, Hwan Geun CHOI
  • Publication number: 20180065969
    Abstract: The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.
    Type: Application
    Filed: August 9, 2017
    Publication date: March 8, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Han Na CHO, Eun Hye JU, Woo Young HUR, Ho Jong YOON, Chi Man SONG
  • Publication number: 20180050036
    Abstract: The present invention relates to a therapeutic agent for chronic myelogenous leukemia with reduced drug-resistance and side-effects containing a 1,6-disubstituted indole compound.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 22, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Ho Jong YOON, Woo Young HUR, Yun Ju NAM, Hwan Geun CHOI
  • Patent number: 9586936
    Abstract: A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an active ingredient.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: March 7, 2017
    Assignee: KOREA INSTITITUE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Ho Jong Yoon, Ji Hye Yoon, Woo Young Hur, Eun Joo Roh, Yeon Ui Kwak
  • Publication number: 20160145240
    Abstract: A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an active ingredient.
    Type: Application
    Filed: November 20, 2015
    Publication date: May 26, 2016
    Inventors: Tae Bo SIM, Ho Jong YOON, Ji Hye YOON, Woo Young HUR, Eun Joo ROH, Yeon Ui KWAK